Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
HKD 3.14
(1.29%)
HKD 3.14
(1.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -397.87 Million CNY | 16.19% |
| 2022 | -474.73 Million CNY | -57.03% |
| 2021 | -302.32 Million CNY | -268.79% |
| 2020 | 179.11 Million CNY | 192.24% |
| 2019 | -194.17 Million CNY | -91.43% |
| 2018 | -101.43 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -92.94 Million CNY | 0.0% |
| 2024 Q1 | -92.94 Million CNY | 12.86% |
| 2023 FY | -397.87 Million CNY | 16.19% |
| 2023 Q2 | -111.05 Million CNY | 0.0% |
| 2023 Q1 | -111.05 Million CNY | 24.13% |
| 2023 Q4 | -106.65 Million CNY | -12.36% |
| 2023 Q3 | -94.92 Million CNY | 14.52% |
| 2022 Q2 | -94.09 Million CNY | 0.0% |
| 2022 FY | -474.73 Million CNY | -57.03% |
| 2022 Q4 | -146.36 Million CNY | 0.0% |
| 2022 Q3 | -146.36 Million CNY | -55.55% |
| 2022 Q1 | -94.09 Million CNY | -15.45% |
| 2021 Q2 | -64.65 Million CNY | 0.0% |
| 2021 Q3 | -81.5 Million CNY | -26.06% |
| 2021 Q4 | -81.5 Million CNY | 0.0% |
| 2021 FY | -302.32 Million CNY | -268.79% |
| 2021 Q1 | -64.65 Million CNY | -144.55% |
| 2020 FY | 179.11 Million CNY | 192.24% |
| 2020 Q4 | 145.14 Million CNY | 0.0% |
| 2020 Q3 | 145.14 Million CNY | 462.37% |
| 2020 Q2 | -40.05 Million CNY | 0.0% |
| 2020 Q1 | -40.05 Million CNY | 43.71% |
| 2019 Q2 | -29.05 Million CNY | 0.0% |
| 2019 Q3 | -71.15 Million CNY | -144.88% |
| 2019 Q4 | -71.15 Million CNY | 0.0% |
| 2019 Q1 | -29.05 Million CNY | 0.0% |
| 2019 FY | -194.17 Million CNY | -91.43% |
| 2018 FY | -101.43 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 687.118% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 144.309% |